Unified Patent Court (UPC) analytics are now available. Check here

Law FirmOpposition Filing Analysis

The comprehensive analysis of Molnia opposition landscape, with a particular emphasis on intellectual property (IP) dynamics.

Stay updated with the latest patent oppositions filed by Molnia

Patent NumberTitleApplicantOpposition DateOpposition Company
EP2818163Composition For Nasal Application With Improved StabilityMARIA CLEMENTINE MARTIN KLOSTERFRAU VERTRIEBSGESELLSCHAFTFeb 26, 2025RATIOPHARM
EP4069368Enhancing Blood-Brain Barrier Drug Transport By Targeting Endogenous RegulatorsTHE UNITED STATES GOVERNMENT REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRSJan 15, 2025DORRIES
EP3110848Methods For Treating Skin Infection By Administering An Il-4R AntagonistSANOFI BIOTECHNOLOGYNov 13, 2024DORRIES
EP3515465Methods For Treating Severe Atopic Dermatitis By Administering An Il-4R InhibitorREGENERON PHARMACEUTICALSNov 7, 2024DORRIES
EP3167888Treatment Of Paroxysmal Nocturnal Hemoglobinuria Patients By An Inhibitor Of ComplementALEXION PHARMACEUTICALSOct 28, 2024AMGEN TECHNOLOGY IRELAND UNLIMITED
EP3791896Combination Therapy Involving Antibodies Against Claudin 18.2 For Treatment Of CancerTRON TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITTSMEDIZIN DER JOHANNES GUTENBERG UNIVERSITT MAINZ GEMEINNTZIGEOct 10, 2024DR H ULRICH DORRIES
EP3973987Methods For Treating Or Preventing Asthma By Administering An Il-4R AntagonistSANOFI BIOTECHNOLOGYOct 1, 2024DR H ULRICH DORRIES
EP3703818Methods For Treating Or Preventing Asthma By Administering An Il-4R AntagonistSANOFI BIOTECHNOLOGYAug 1, 2024DR H ULRICH DORRIES
EP4011915Methods For Treating Or Preventing Asthma By Administering An Il-4R AntagonistREGENERON PHARMACEUTICALSJul 3, 2024DR H ULRICH DORRIES
EP3536712Methods For Reducing Lipoprotein(A) Levels By Administering An Inhibitor Of Proprotein Convertase Subtilisin Kexin-9 (Pcsk9)REGENERON PHARMACEUTICALSFeb 29, 2024AMGEN